All else equal, this would increase gasoline prices, which in most of the country have averaged $3 per gallon for the past year amid historically low levels of petroleum inventories (see chart). But Trump wants lower gasoline prices, which is why if the oil tariffs come at all, they will likely start slowly.

Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), which currently trades at $438.40 with a market capitalization of $112.

Commerce Secretary nominee Howard Lutnick defended Tether in a Senate hearing, arguing AI will "rid the world of criminals" using blockchain.

Cantor Fitzgerald analyst C J Muse maintained a Hold rating on Intel (INTC – Research Report) yesterday and set a price target of $22.00. The

KoBold is part of something called the Disko-Nuussuaq project, a mining effort to drill for minerals along Greenland’s western coast. It has also secured a Mineral Exploration License for Disko Island—which is located off Greenland’s west coast—for the years 2024-30.

Billionaire financier Howard Lutnick, President Donald Trump’s choice to lead the Commerce Department, said Wednesday that he would sell all of his business holdings within 90 days.

Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer

Cantor Fitzgerald CEO and Commerce Secretary nominee Howard Lutnick became visibly emotional at his confirmation hearing Wednesday as he recalled the more than 650 employees — including his

Howard Lutnick, the financier President Trump has picked to lead the Commerce Department, said he favored “across-the-board” tariffs and was grilled about his financial ties in a nomination hearing Wednesday.

Howard Lutnick, President Donald Trump's nominee for Commerce Secretary and CEO of Cantor Fitzgerald, says the firm has no equity in Tether, a controversial crypto firm. But he does say Cantor owns a convertible bond with Tether.

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care first-time share sales since October.

Fintel reports that on January 30, 2025, Cantor Fitzgerald upgraded their outlook for Lam Research (NasdaqGS:LRCX) from Neutral to Overweight. Analyst Price Forecast Suggests 13.99% Upside As of January 28,